All In Biotech

Drug Trial Radar · NCT00739453

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Oct 23, 2008

Primary completion

Mar 3, 2012

Study completion Mar 3, 2012

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Aug 21, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib

Conditions

  • Advanced Solid Tumors

Interventions

  • OSI-906Drug

    administered orally

  • erlotinibDrug

    administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the maximum tolerated dose (MTD) and recommended phase 2 dose of OSI-906 and erlotinibTime frame: 21 days

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Colorado Health Science Center

    Aurora, Colorado

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Hudson-Webber Cancer Research Center, Karmanos Cancer Institute

    Detroit, Michigan

  • University of Oxford Department of Medical Oncology

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.